Fore Biotherapeutics News
21 articles
FORE Biotherapeutics Announces $75M in Series D Financing and CEO Transition
FORE Biotherapeutics Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
FORE Biotherapeutics Receives FDA Orphan Drug Designation for FORE8394 for the Treatment of Primary Brain and CNS Malignancies
Fore Biotherapeutics Announces First Patient Dosed in Global Phase 2 Trial Evaluating FORE8394 in BRAF-Mutated Solid and Brain Tumors
Fore Biotherapeutics Announces Fast Track Designation Granted by FDA to FORE8394 for the Treatment of Cancers Harboring BRAF Class 1 and Class 2 Alterations
Fore Biotherapeutics to Present Phase 1/2a Data on FORE8394, a Next-Generation BRAF Inhibitor, at ESMO 2022
Fore Biotherapeutics Appoints Matthew E. Ros as Chief Executive Officer
ForeBio is on its way to Nasdaq at a $500 million valuation
Israeli biotechnology company Fore Biotherapeutics is considering going public on Nasdaq with a $500 million valuation. The company plans to raise $100 million in an April IPO. Pontifax and OrbiMed, who previously invested $21 million, are expected to make a $120 million profit. Other investors include HBM Healthcare, Pharma Novartis’s investment fund, Cormorant Asset Management, and SR One Capital Management. Fore Biotherapeutics, formerly known as NovellusDX, is developing a drug that inhibits the mutation of the BRAF gene. The company has raised $71 million since its founding in 2011 and has obtained a license from Japanese company Plexxikon for research. The companys shareholders include its founders, Pontifax, and other investment funds.
Public TradingInvestment
A diagnostics company completes its pharma makeover, rebranding as Fore with Immunomedics vet at the helm
Israeli diagnostics company Novellus has rebranded as Fore Biotherapeutics and appointed Usama Malik as CEO. The company plans to utilize its genomics-based platform to in-license programs and screen them for optimal use.
Acquisition
NovellusDx Establishes Fore Biotherapeutics U.S. as its Operating Company in the United States & Appoints Dieter Weinand as Chairman of the Board & Usama Malik as Chief Executive Officer and Director of the Board
Novellus and Tempus Announce Collaboration to Accelerate Clinical Trial Patient Enrollment
Novellus Closes $57M Series C Financing
Novellus snaps up BRAF cancer drug from Daiichi's biotech unit Plexxikon
The article does not provide any information about Questex LLC.
Cancer Genetics Settles Failed Merger Deal With NovellusDx;Receives $6M From Interpace
Cancer Genetics has resolved all outstanding issues related to its failed merger with NovellusDx. The company received a $6 million payment from the sale of its biopharma business to Interpace Diagnostics. It has also restructured a loan agreement with an unsecured lender. Cancer Genetics will pay NovellusDx $1.1 million in cash and $450,000 over a nine-month period to settle all matters between the companies. The company has hired HC Wainwright to help identify another potential acquisition, merger, business combination, or strategic transaction. Additionally, Cancer Genetics received $6 million in cash from Interpace as partial settlement of a $7.7 million promissory note. The company has entered into a note purchase agreement with Atlas Sciences to borrow $1.25 million. Cancer Genetics announced a 1-for-30 reverse stock split.
AcquisitionInvestmentManagement Changes
The Gene Editing Institute licenses CRISPR technology to NovellusDx to drive next-generation cancer care - ChristianaCare News
The Gene Editing Institute has licensed CRISPR technology to NovellusDx to drive next-generation cancer care.
Partners
Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge
Cancer Genetics, Inc. and NovellusDx have announced a definitive agreement to merge, with NovellusDx shareholders receiving approximately 49% of the equity of Cancer Genetics. The merger aims to create a leading precision medicine company in the field of oncology, combining Cancer Genetics test portfolio and tumor biology data with NovellusDxs technology and machine learning capabilities. The combined company plans to accelerate therapeutic development and improve treatment success rates for biopharma companies. The merger is expected to close in the first quarter of 2019, subject to shareholder and regulatory approvals. Cancer Genetics CEO, John A. Roberts, will become CEO of the combined company.
Acquisition
Israeli cancer profiling co NovellusDx raises $6m
Israeli functional genomics and cancer profiling company NovellusDx has completed a $6 million financing round. The funds will be used to accelerate the execution of the companys strategy, move into commercialization, and meet the need for functional oncology worldwide. NovellusDxs technology monitors signaling pathways and identifies driver mutations in cancer patients. The company provides concise reports for oncologists, outlining the contribution of each driver mutation and the effects of targeted therapy options. The financing round included participation from Helsinn Investment Fund S.A. SICAR, Bio Capital Impact Fund, and Windham Venture Partners.
Investment
NovellusDx Announced Today the Completion of the First Phase of an In-vitro Study of BioMed Valley Discoveries' BVD523
NovellusDx has completed the first phase of an in-vitro study to characterize the functional activity of ERK1/2 mutations and their response to BioMed Valley Discoveries lead compound. The study aims to accelerate drug development and potentially help more patients with a live-cell based assay to monitor mutations and their response to drugs. BioMed Valley Discoveries is a clinical stage biotechnology company focused on addressing unmet medical needs. NovellusDxs mission is to provide functional information about mutations and their responses to drugs. They are based in Jerusalem, Israel.
Partners
Personalized Cancer Therapy on the Horizon Thanks to New Genomic Cancer Research Partnership
The Gene Editing Institute of Christiana Care Health System’s Helen F. Graham Cancer Center & Research Institute has been awarded a grant of $900,000 from the U.S.-Israel Binational Industrial Research and Development (BIRD) Foundation in partnership with the biotechnology company NovellusDx. The grant allows the Gene Editing Institute to partner with NovellusDx on a new series of gene editing technologies for personalized cancer therapies. The partnership aims to accelerate progress in personalized medicine for cancer and commercialize the gene editing technologies that result from the research.
Partners
OrbiMed invests $2.5m in cancer profiling co NovellusDx
Israeli cancer profiling developer NovellusDx has raised $12.5 million in its latest funding round, with OrbiMed Advisors LLC contributing $2.5 million. The funding round is led by IntraCure and includes Pontifax venture capital fund. NovellusDxs technology monitors signaling pathways and identifies driver mutations, providing a concise report for oncologists. The investment will be used for R&D and to expand the companys commercial service lab. NovellusDx was founded in 2011 and had previously raised $6 million.
InvestmentExpand
Israeli cancer profiling co NovellusDx raises $10m
Israeli cancer profiling company NovellusDx Ltd. has raised $10 million in a financing round led by investor InterCure Ltd. The company, which develops personalized medicine technology to treat cancer, has raised a total of $16 million to date. The latest investment could expand to $20 million if certain milestones are achieved. NovellusDxs technology is based on a functional assay that detects dis-regulated translocation of mutated signaling proteins to the nucleus, allowing the company to identify functionally-impactful driver mutations. The personalized medicine technology enables NovellusDx to profile the oncogenic activity at the cellular level of the tumor and monitor the effects of drug administration.
Investment
